

Q1 parenchyma or through a surgically inserted shunt into the lateral cerebro ventricle of the brain.

33. A method as claimed in claim 30 wherein GPE is administered by cerebro-ventricular injection.

34. A method as claimed in claim 12 wherein GPE is administered in combination with artificial cerebrospinal fluid.

35. A method as claimed in claim 33 wherein GPE is administered in combination with artificial cerebrospinal fluid.

36. A method as claimed in claim 12 wherein GPE is administered through an intravenous, oral, rectal, nasal, subcutaneous, inhalation, intraperitoneal or intramuscular route.

37. A method as claimed in claim 36 wherein GPE is administered by intraperitoneal injection.

REMARKS

Entry of the added claims is respectfully requested. The claims find support in the specification and claims as originally filed. For example, treatment of glial cells is disclosed at, e.g., page 10, lines 10-11 and line 23. Treatment of non-dopaminergic cells is disclosed where neuroprotective effects on non-dopaminergic cells, such as, e.g., hippocampal cells, are disclosed. Such discussion may be found at, e.g., page 10, lines 26-30;; page 16, lines 22-24; Figs. 2-6. Treatment prior to parturition or to elective surgery, such as cardiac or brain surgery, is disclosed at, e.g., page 5, lines 1-3 and at page 24, lines 7-8. Administration via maternal circulation is disclosed at, e.g., page 18, lines 23-24. Administration of GPE where cell bodies of neural and glial cells are located is disclosed at,


e.g., page 4, lines 10-13. Use of electrophoretic procedures during administration of GPE is disclosed at, e.g., page 7, line 9. No new matter is added by the amendment.

CONCLUSION

Entry of the amendment and consideration and allowance of the claims is respectfully requested.

The Commissioner is authorized to charge any fees and to credit any overpayment which may be required in connection with this paper under 37 CFR \$1.16 and \$1.17, to Deposit Account No. 08-1641, referencing Docket No. 37522-1002C1. A duplicate copy of this form is enclosed.

Respectfully submitted,



Date: August 31, 2001

By:

James A. Fox
Attorney for Applicants
Reg. No. 38,455

Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park, California 94025-3506
(650) 324-7014